Sernova (TSE:SVA) Hits New 12-Month Low – Should You Sell?

Shares of Sernova Corp. (TSE:SVAGet Free Report) hit a new 52-week low during trading on Monday . The company traded as low as C$0.14 and last traded at C$0.14, with a volume of 43015 shares trading hands. The stock had previously closed at C$0.14.

Sernova Price Performance

The firm has a market capitalization of C$44.37 million, a price-to-earnings ratio of -2.70 and a beta of 0.67. The business’s 50-day moving average is C$0.17 and its two-hundred day moving average is C$0.18. The company has a debt-to-equity ratio of -4.40, a quick ratio of 18.11 and a current ratio of 0.32.

Sernova Company Profile

(Get Free Report)

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues.

Read More

Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.